Li Chen, Mengmeng Sun, Huajun Zhang, Xinghai Zhang, Yanfeng Yao, Ming Li, Kangyin Li, Pengfei Fan, Haiwei Zhang, Ye Qin, Zhe Zhang, Entao Li, Zhen Chen, Wuxiang Guan, Shanshan Li, Changming Yu, Kaiming Zhang, Rui Gong, Sandra Chiu
Nipah virus (NiV) is a World Health Organization priority pathogen and there are currently no approved drugs for clinical immunotherapy. Through the use of a naïve human phage-displayed Fab library, two neutralizing antibodies (NiV41 and NiV42) targeting the NiV receptor binding protein (RBP) were identified. Following affinity maturation, antibodies derived from NiV41 display cross-reactivity against both NiV and Hendra virus (HeV), whereas the antibody based on NiV42 is only specific to NiV. Results of immunogenetic analysis reveal a correlation between the maturation of antibodies and their antiviral activity...
April 6, 2024: Nature Communications